Biotechnology

Apimeds Pharmaceuticals US

Apimeds Pharmaceuticals US released FY2025 9 Months earnings on November 12 (EST), actual revenue USD 0, actual EPS USD -0.4492

Apimeds Pharmaceuticals US released FY2025 Q3 earnings on November 12, 2025 (EST) with actual revenue of USD 0 and EPS of USD -0.1416

Apimeds Pharmaceuticals US released FY2025 Q2 earnings on August 19 (EST) with actual revenue of USD 0 and EPS of USD -0.2567

Apimeds Pharmaceuticals US released FY2025 Semi-Annual Earnings on August 19 (EST), with actual revenue of USD 0 and EPS of USD -0.3349

Apimeds Pharmaceuticals US released FY2025 Q1 earnings on May 20, 2025, EST with actual revenue of USD 0 and EPS of USD -0.0509

Apimeds Pharmaceuticals US released FY2024 Q4 earnings on April 15, 2025 (EST) with actual revenue of USD 0 and EPS of USD -0.0394

Apimeds Pharmaceuticals US released FY2024 annual earnings on April 15, 2025 (EST), with actual revenue of USD 0 and EPS of USD -0.1758

APUS.US released FY2023 Q3 earnings on December 9, 2024 (BJT) with actual revenue of 0 USD and EPS of -0.0253 USD

APUS.US released FY2024 9 Months Earnings on December 9 (BJT), with actual revenue of 0 USD and EPS of -0.1364 USD

APUS.US released FY2023 9 Months Earnings on December 9 (BJT), with actual revenue of 0 USD and EPS of -0.0515 USD

APUS.US released FY2024 Q3 earnings on December 9 (BJT), actual revenue 0 USD, actual EPS -0.042 USD

APUS.US released FY2024 Semi-Annual Earnings on September 25 (BJT), with actual revenue of 0 USD and EPS of -0.0943 USD

APUS.US released FY2023 Q4 earnings on September 25 (BJT) with actual revenue of 0 USD and EPS of -0.089 USD

APUS.US released FY2022 Q4 earnings on September 25 (BJT) with actual revenue of 0 USD and EPS of -0.0193 USD

APUS.US released FY2024 Q2 earnings on September 25 (BJT) with actual revenue of 0 USD and EPS of -0.0568 USD

APUS.US released FY2022 Annual Earnings on September 25 (BJT), with actual revenue of 0 USD and EPS of -0.1738 USD

APUS.US released FY2023 Semi-Annual Earnings on September 25 (BJT) with actual revenue of 0 USD and EPS of -0.0261 USD

APUS.US released FY2023 Annual Earnings on September 25 (BJT), with actual revenue of 0 USD and EPS of -0.1691 USD

APUS.US released FY2023 Q2 earnings on September 25 (BJT) with actual revenue of 0 USD and EPS of -0.0093 USD

APUS.US released FY2024 Q1 earnings on August 5 (BJT) with actual revenue of 0 USD and EPS of -0.0375 USD

< 1B

1B - 5B

5B - 10B

10B - 50B

50B - 100B

100B - 500B

500B - 1T

≥ 1T

Market Value

Total Assets

< 100M

100M - 500M

500M - 1B

≥ 100B

Revenue

0 - 50M

50M - 100M

≥ 10B

Profits

< 0%

0% - 5%

5% - 10%

10 - 15%

15% - 20%

20 - 25%

25% - 30%

>= 30%

ROE(TTM)

= 0%

0% - 1%

1% - 3%

3% - 5%

5% - 8%

8% - 10%

>= 10%

Dividend Yield

0% - 10%

10% - 15%

20% - 30%

30% - 40%

40% - 50%

>= 50%

Net Profit Margin

0 - 0.05

0.05 - 0.1

0.1 - 0.2

0.2 - 0.4

0.4 - 0.6

0.6 - 0.8

0.8 - 1

>= 1

Asset Turnover

< 1.5

1.5 - 2

2 - 3

3 - 5

5 - 10

10 - 15

15 - 20

>= 20

Equity Multiplier

< 10%

10% - 30%

30% - 50%

50% - 70%

70 - 80%

80% - 90%

90% - 95%

>= 95%

Debt Ratio

AMPLITECH GROUP INC. USD0.001 S/R 20/11/26 SER B

InMed Pharmaceuticals

NextNRG

Amesite

AMPLITECH GROUP INC. COM USD0.001 (S/R 18/07/2026)

Meiwu Tech

QUARTZSEA ACQUISITION CORP ORD USD0.0001 (18/02/2030) (S/R)

CN Energy

Generation Income Properties

MetaVia

ZYBT

APUS

LGVN

In Monday's pre-market session, several health care stocks saw significant movement. Alpha Tau Medical (DRTS) rose 13.5% to $9.66, while Zhengye Biotechnology (ZYBT) increased by 12.69% to $1.07. Valneva (VALN) shares climbed 11.98% to $6.26, and Exagen (XGN) rose 11.88% to $3.3. Conversely, First Tracks (TRAX) fell 13.2% to $16.97, and Aditxt (ADTX) dropped 12.88% to $0.1. Other notable losers included Apimeds Pharmaceuticals (APUS) and Longeveron (LGVN), which saw declines of 10.7% and 8.9%, respectively.

benzinga_article

Zhengye Biotechnology

Longeveron

Alpha Tau Medical

Valneva SE

Aditxt

First Tracks Biotherapeutics

Exagen

iShares Biotechnology ETF

First Trust NYSE Arca Biotech Index Fd

SPDR S&P Biotech

Direxion S&P Biotech Bull 3X

iShares US Medical Devices

Decoy Therapeutics

BridgeBio Oncology Therapeutics

Certara

XORTX Therapeutics

ALPHA TAU MEDICAL LTD C/WTS (TO PUR COM)

12 Health Care Stocks Moving In Monday's Pre-Market Session

CVGI

SKYX

In Wednesday's trading session, BlueLinx Holdings (NYSE:BXC) saw a significant gain of 28.8%, reaching $59.5, following its Q1 earnings report. Other notable gainers included SKYX Platforms (NASDAQ:SKYX) up 26.38%, Commercial Vehicle Group (NASDAQ:CVGI) up 24.17%, and GEO Group (NYSE:GEO) up 23.31%. Conversely, Primoris Services (NYSE:PRIM) experienced a sharp decline of 50.6% to $100.14, along with Limbach Holdings (NASDAQ:LMB) down 35.14% and Phoenix Asia Holdings (NASDAQ:PHOE) down 33.74%.

Bluelinx

Commercial Vehicle

SKYX Platforms

NANO Nuclear Energy

Skycorp Solar

Primoris

Limbach

Phoenix Asia

Cre8 Enterprise - CL

Globavend

Broadwind

12 Industrials Stocks Moving In Wednesday's Intraday Session

AVTX

TMDX

PAVM

AKAN

MNKD

GCTK

In Wednesday's pre-market session, Avalo Therapeutics (AVTX) saw a significant gain of 50.9%, reaching $24.53, while GlucoTrack (GCTK) rose by 45.2% to $1.06. Other notable gainers included Simulations Plus (SLP) up 35.66% and MannKind (MNKD) up 20.27%. Conversely, PAVmed (PAVM) dropped 27.9% to $5.8, and Apimeds Pharmaceuticals (APUS) fell 27.67% to $2.17. TransMedics Group (TMDX) and Akanda (AKAN) also experienced declines of 22.04% and 19.22%, respectively. The fluctuations follow recent earnings reports for Q1 and Q4.

Avalo Therapeutics

TransMedics

PAVmed

Akanda

Simulations Plus

Mannkind

GlucoTrack

Cypherpunk Tech

Atlantic

Hyperion DeFi

Alphatec

ATLANTIC INTERNATIONAL CORP C/WTS 31/08/2026 (TO PUR COM)

PAVMED INC C/WTS 30/04/2025(TO PUR COM) CLASS Z

12 Health Care Stocks Moving In Wednesday's Pre-Market Session

Apimeds Pharmaceuticals US, Inc. has appointed Sungjoon Chae as Co-Chief Executive Officer, effective May 4, 2026. This decision follows a stockholder nomination, with no related-party relationships involved. Chae's background in real estate development suggests a focus on complex project management within the pharmaceutical sector. The announcement emphasizes the leadership change rather than detailing the company's drug portfolio or commercial strategy. Apimeds currently has a market cap of $23.64M and an average trading volume of 172,242.

Tip Ranks

Apimeds Names Sungjoon Chae Co-Chief Executive Officer

Apimeds Pharmaceuticals US Settles with Inscobee; Merger Proceeds, $100 Million PIPE Financing to Close, and Lōkahi Therapeutics to Advance Apitox Program | APUS Stock News

StockTitan

Invesco Biotechnology & Genome ETF

iShares US Pharma

Health Care Select Sector SPDR

Ark Genomic Revolution ETF

Invesco Nasdaq Biotechnology ETF

Proshares Ultra Nasdaq Biotech

iShares Global Healthcare

VanEck Biotech ETF

ALPS Medical Breakthrough

Apimeds Pharmaceuticals US Settles with Inscobee; Merger Proceeds, $100 Million PIPE Financing to Close, and Lōkahi Therapeutics to Advance Apitox Program | APUS Stock News

Apimeds Pharmaceuticals US, Inc. reported a net loss of $6M for FY 2025 on $0 revenue, compared to a $1.4M loss in FY 2024. The diluted EPS was $(0.55) based on 10.88M shares. The company completed its NYSE IPO on May 12, 2025, raising approximately $11.6M. It also acquired MindWave, expanding into digital assets. R&D spending reached $1.6M, with plans for further funding and clinical advancements through 2026.

TradingView

Apimeds Pharmaceuticals US FY 2025: Revenue $0 Net loss $6M, EPS $(0.55) — 10-K Summary

Earnings Watch

Apimeds Pharmaceuticals US | 10-K: FY2025 Revenue: USD 0

Apimeds Pharmaceuticals US, Inc. has secured a forbearance agreement from its senior noteholder, Alto Opportunity Master Fund, until June 30, 2026, as part of its strategy to address listing compliance issues. The company recently reached a confidential settlement with Inscobee Inc. and Apimeds Korea, resolving disputes from a previous merger and ensuring a $4 million working capital contribution. The agreement includes conditions for SEC filings, NYSE compliance, and a reverse stock split, emphasizing the importance of executing its remediation and listing strategy to maintain its NYSE American listing.

Apimeds Secures Forbearance to Support Listing Remediation

Apimeds Pharmaceuticals US(APUS.US)

Valuation analysis

Institutional View & Shareholder

Analyst Ratings

12 Health Care Stocks Moving In Monday's Pre-Market Session

12 Industrials Stocks Moving In Wednesday's Intraday Session

12 Health Care Stocks Moving In Wednesday's Pre-Market Session

Apimeds Names Sungjoon Chae Co-Chief Executive Officer

Apimeds Pharmaceuticals US Settles with Inscobee; Merger Proceeds, $100 Million PIPE Financing to Close, and Lōkahi Therapeutics to Advance Apitox Program | APUS Stock News